Alembic Pharmaceuticals Ltd
NSE:APLLTD
Alembic Pharmaceuticals Ltd
Gross Profit
Alembic Pharmaceuticals Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alembic Pharmaceuticals Ltd
NSE:APLLTD
|
Gross Profit
₹47.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Gross Profit
₹220.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Gross Profit
₹181.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Gross Profit
₹411.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Gross Profit
₹85.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Gross Profit
₹69.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alembic Pharmaceuticals Ltd
Glance View
Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe. The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.
See Also
What is Alembic Pharmaceuticals Ltd's Gross Profit?
Gross Profit
47.8B
INR
Based on the financial report for Dec 31, 2024, Alembic Pharmaceuticals Ltd's Gross Profit amounts to 47.8B INR.
What is Alembic Pharmaceuticals Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
14%
Over the last year, the Gross Profit growth was 10%. The average annual Gross Profit growth rates for Alembic Pharmaceuticals Ltd have been 8% over the past three years , 7% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet